Exelixis
EXEL
#2083
Rank
$7.22 B
Marketcap
$23.83
Share price
-0.13%
Change (1 day)
27.71%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/E ratio for Exelixis (EXEL)

P/E ratio as of March 2024 (TTM): 84.2

According to Exelixis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 84.2217. At the end of 2022 the company had a P/E ratio of 28.1.

P/E ratio history for Exelixis from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202228.113.92%
202124.7-54.46%
202054.2226.32%
201916.694.37%
20188.55-85.09%
201757.4-226.95%
2016-45.2540.88%
2015-7.05580.52%
2014-1.04-77.69%
2013-4.64-6.51%
2012-4.97-158.69%
20118.46-187.63%
2010-9.6665.13%
2009-5.8578.27%
2008-3.28-66.92%
2007-9.9228.95%
2006-7.69-11.81%
2005-8.7273.53%
2004-5.033.38%
2003-4.86-7.01%
2002-5.23-51.55%
2001-10.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
11.2-86.68%๐Ÿ‡บ๐Ÿ‡ธ USA
14.9-82.27%๐Ÿ‡บ๐Ÿ‡ธ USA
20.2-75.98%๐Ÿ‡บ๐Ÿ‡ธ USA
15.6-81.50%๐Ÿ‡ซ๐Ÿ‡ท France
72.3-14.13%๐Ÿ‡บ๐Ÿ‡ธ USA
13.4-84.07%๐Ÿ‡บ๐Ÿ‡ธ USA
12.3-85.42%๐Ÿ‡ฌ๐Ÿ‡ง UK
-1.09-101.29%๐Ÿ‡บ๐Ÿ‡ธ USA
-17.9-121.20%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.